ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CYPH / forecast
TTRX (38) ARCT (25) AVIR (33) ENTA (20) ⌘ Pro Terminal →

Cypherpunk Technologies Inc. (CYPH) 12-Month Stock Forecast & Price Target Cone

$2.36 -20.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.27

Cypherpunk Technologies Inc. (CYPH) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $321.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CYPH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CYPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Cypherpunk Technologies Inc. (NASDAQ: CYPH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $2.36 (-20.80% 1D, market cap $321.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CYPH ranks #425 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CYPH compare to TTRX and ARCT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CYPH carries a Roarable D- (42/100 RQD), trailing P/E of 71.3x, gross margin of —, and ROIC of -23.3%. By comparison, TTRX (Turn Therapeutics Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -28.3%, cap $318.5M) and ARCT (Arcturus Therapeutics Holdings Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CYPH?
▼

Per CYPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001509745), Cypherpunk Technologies Inc. generated $115.0M in revenue (-41.4% YoY), $5.0M in net income, and -$43.9M in free cash flow against $163.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.27 (-3.93%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510042
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (4)Whales (14)SEC (10)Macro (11)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-7.2% Base Target
$4 Bull$2 Base$2 Bear
📬 FREE CYPH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CYPH)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY CYPH SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (26% of score)

FRED Regime × Technicals: 52% of 52W Range • RSI-14 at 50.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
50
Grade C-$2.84-1.1% Next Q
Q2 (-2Q)
47
Grade D$2.81+11.4% Next Q
Q3 (-1Q)
45
Grade D$3.13-24.6% Next Q
Current
42
Grade D-$2.36-7% Hist 90D α
Trajectory: C- (50) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CYPH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CYPH currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.81) and Max Pain ($2.48) forces dealer call-delta covering toward $4.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CYPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CYPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 42%NO 58%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CYPH Position Size: $10,000

Shares at $2.36: 4237.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $1.71
$7,246
$-2,754 (-27.5%)
12M Consensus BaseTarget $2.19
$9,280
$-720 (-7.2%)
12M Bull Case BreakoutTarget $4.40
$18,644
+$8,644 (+86.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$469%B
JP MorganUS Large-Cap ResearchSELL$258%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CYPH)

  • ✓Walkthrough of CYPH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CYPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +140.82%▲ ASCENDING CHANNEL
2026-11-03O $3.31H $3.31L $2.36C $2.36VOL 14.41M
RES: $4.99SUP: $0.77SMA50: $2.81SMA200: $1.30
$4.45$3.38$2.30$1.23$0.16RES $4.99SUP $0.77$2.362026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CYPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CYPH Butterfly Map → + Track CYPH →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
46.4%/yr Implied 5Y Growth

vs. -41.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CYPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CYPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CYPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CYPH)

Health Care Rank #425 of 1015 ⚔️ TTRX vs CYPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CYPH vs. TTRX, ARCT, AVIR, ENTA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cypherpunk Technologies Inc. (CYPH) ranks #425 by composite RQD confidence (42/100, grade D-) and #507 by equity capitalization ($321.1M). Within this direct 5-issuer industry benchmark cohort, CYPH leads on earnings valuation at 71.3x trailing P/E, while CYPH leads on capital efficiency and profitability with -23.3% ROIC and — gross margin. CYPH currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CYPH ACTIVE
Cypherpunk Technologies Inc.
D- 42/100 71.3x — -23.3% -20.80% $321.1M Benchmark Subject
TTRX
Turn Therapeutics Inc.
D- 38/100 — — -28.3% -7.48% $318.5M /ttrx-vs-cyph →
ARCT
Arcturus Therapeutics Holdings Inc.
E 25/100 — — -35.0% -13.96% $313.5M /arct-vs-cyph →
AVIR
Atea Pharmaceuticals Inc.
E 33/100 — — -35.0% -0.24% $329.6M /avir-vs-cyph →
ENTA
Enanta Pharmaceuticals Inc.
E 20/100 — — -35.0% -2.61% $311.9M /enta-vs-cyph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001509745 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cypherpunk Technologies Inc. (CYPH) reported GAAP revenue of $115.0M (-41.4% vs. FY2024 revenue of $196.2M , and -52.8% cumulative change since FY2023) , GAAP net income of $5.0M, operating cash flow of -$43.9M, and free cash flow of -$43.9M (+27.2% YoY). On the balance sheet, CYPH closed FY2025 with $163.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $115.0M $5.0M -$43.9M -$43.9M $163.2M —
FY2024 (FY) 2024-12-31 $196.2M -$68.0M -$60.3M -$60.3M $49.1M —
FY2023 (FY) 2023-12-31 $243.7M -$81.0M -$43.8M -$43.8M — —

3. CYPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CYPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cypherpunk Technologies Inc. (NASDAQ: CYPH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $2.36 (-20.80% 1D, market cap $321.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CYPH ranks #425 in composite RQD confidence.

How does CYPH compare to TTRX and ARCT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CYPH carries a Roarable D- (42/100 RQD), trailing P/E of 71.3x, gross margin of —, and ROIC of -23.3%. By comparison, TTRX (Turn Therapeutics Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -28.3%, cap $318.5M) and ARCT (Arcturus Therapeutics Holdings Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CYPH?

Per CYPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001509745), Cypherpunk Technologies Inc. generated $115.0M in revenue (-41.4% YoY), $5.0M in net income, and -$43.9M in free cash flow against $163.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CYPH trading relative to its 50-day, 200-day, and 52-week technical levels?

CYPH last traded at $2.36 (-20.80% on volume of 19,154,109 shares), positioning the stock -16.01% below its 50-day simple moving average ($2.81) and +81.54% above its 200-day simple moving average ($1.30). Across its 52-week range of $0.39 to $4.19, CYPH sits at the 51.8% percentile with a 14-day RSI of 50.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.07 to $2.65).

Direct Sub-Reports: CYPH RQD Cockpit CYPH 12M Forecast CYPH Earnings & Move CYPH Dividends & DRIP CYPH Insiders & 13F CYPH Whale Options CYPH Profit Sankey CYPH News & Why
ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CYPH — Cypherpunk Technologies Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cypherpunk Technologies Inc. (CYPH) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.36 (-20.80% 1D, market capitalization $321.1M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -23.3%, gross margin of —, operating margin of —, and free cash flow yield of -12.31%.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cypherpunk Technologies Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..4B. Reported revenue is — in each listed period. —: products sold, customer base, and revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cypherpunk Technologies Inc. (CYPH) reported $115.0M in annual revenue (up from $196.2M in FY2024, -41.4% YoY) and $5.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($243.7M revenue, -$81.0M net income) through FY2025, CYPH scaled operating cash flow to -$43.9M and free cash flow to -$43.9M, backed by $163.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 42/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -12.31% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $0.39 – $4.19 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 71.3x trailing P/E against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), CYPH carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can CYPH sustain or expand its — operating margin and -23.3% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $115.0M and free cash flow of -$43.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CYPH's 66.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CYPH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cypherpunk Technologies Inc. (CYPH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CYPH Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CYPH Bull vs. Bear Conversation Board — What's Your Call at $2.36?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CYPH 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CYPH:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $3.93 (+31.9%)
📌 Pinned Debate

Whale 13F flow scores 17 of 20, the strongest RQD pillar, indicating meaningful institutional accumulation and options positioning.

Long CYPH at $2.98 targeting $3.93. Whale 13F flow scores 17 of 20, the strongest RQD pillar, indicating meaningful institutional accumulation and options positioning.. Institutional whale score is 14/20 and the risk/reward vs. the $0.55 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

Both sides have a point here — CYPH's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $2.32 (-22.1%)
Spot @ $2.98

Fundamental Cash Engine scores 4 of 20 with ROIC at -23.3% and FCF yield at -12.31%, and operating income and FCF were negative in all

Sitting on the sidelines or leaning short CYPH above $2.98. Fundamental Cash Engine scores 4 of 20 with ROIC at -23.3% and FCF yield at -12.31%, and operating income and FCF were negative in all three reported periods.. Until Fundamental Cash Engine (4/20) and FCF yield (-12.31%) inflect higher, upside is capped near $4.19.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%